http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 30 Apr 2025 07:02:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html <p>XORTX Therapeutics Inc. ("<strong>XORTX</strong>" or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence to support the Company’s XRx-026 program for the treatment http://www.streetinsider.com/Corporate+News/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html Wed, 30 Apr 2025 07:02:13 -0400 ANUA XRTX http://www.streetinsider.com/Corporate+News/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html <p>XORTX Therapeutics Inc. ("<strong>XORTX</strong>" or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence to support the Company’s XRx-026 program for the treatment http://www.streetinsider.com/Corporate+News/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html Wed, 30 Apr 2025 07:02:13 -0400 ANUA XRTX http://www.streetinsider.com/FDA/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html <p>XORTX Therapeutics Inc. ("<strong>XORTX</strong>" or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence to support the Company’s XRx-026 program for the treatment http://www.streetinsider.com/FDA/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html Wed, 30 Apr 2025 07:02:13 -0400 ANUA XRTX http://www.streetinsider.com/FDA/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html <p>XORTX Therapeutics Inc. ("<strong>XORTX</strong>" or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence to support the Company’s XRx-026 program for the treatment http://www.streetinsider.com/FDA/XORTX+Therapeutics+Inc+%28XRTX%29+Provides+Update+on+FDA+Type+B+Meeting+Request/24712135.html Wed, 30 Apr 2025 07:02:13 -0400 ANUA XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Press+Releases/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html <p align="center">● <strong>XORTX will focus on key steps </strong><br/><strong>to advance a NDA filing for Gout indication </strong>●</p> <p align="justify">CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce it has received responses from the US Food and Drug Administration (the “FDA”) and clarified key steps for a new drug application (“NDA”) for the Company’s novel proprietary formulation of oxypurinol for the treatment http://www.streetinsider.com/Globe+Newswire/XORTX+Provides+Update+on+FDA+Type+B+Meeting+Request/24712005.html Wed, 30 Apr 2025 07:00:00 -0400 A.06822034 A.50208731 ANUA O.02555813 O.20026344 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html <p align="justify">CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html Mon, 28 Apr 2025 07:00:00 -0400 A.03718595 A.50208731 ANUA O.02555813 O.04906507 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html <p align="justify">CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html Mon, 28 Apr 2025 07:00:00 -0400 A.03718595 A.50208731 ANUA O.02555813 O.04906507 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html <p align="justify">CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html Mon, 28 Apr 2025 07:00:00 -0400 A.03718595 A.50208731 ANUA O.02555813 O.04906507 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html <p align="justify">CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html Mon, 28 Apr 2025 07:00:00 -0400 A.03718595 A.50208731 ANUA O.02555813 O.04906507 O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html <p align="justify">CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other http://www.streetinsider.com/Press+Releases/XORTX+Announces+Grant+of+European+Patent/24693499.html Mon, 28 Apr 2025 07:00:00 -0400 A.03718595 A.50208731 ANUA O.02555813 O.04906507 O.28734418 XRTX XRTX